Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05252676
Other study ID # IRB2106237-23
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date December 1, 2022

Study information

Verified date July 2023
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is one of the Eastern Cooperative Thoracic Oncology Projects (ECTOP-1011). It aims to evaluate the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma via whole-mount section.


Description:

The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studies demonstrated the ground-glass components might be invasive lesions. Therefore, it is of considerable significance to establish the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date December 1, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ground glass opacity featured lung nodule diagnosed by thin-section computed tomography(TSCT) - Pre-operation clinical IA stage - Pulmonary lobectomy or segmentectomy - Provision of informed consent Exclusion Criteria: - Postoperative diagnosis of non-adenocarcinoma or mucinous adenocarcinoma - The surgical specimens fail to satisfy requirement of inflation and formalin fixation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Fudan University Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

References & Publications (10)

Isaka T, Yokose T, Ito H, Imamura N, Watanabe M, Imai K, Nishii T, Woo T, Yamada K, Nakayama H, Masuda M. Comparison between CT tumor size and pathological tumor size in frozen section examinations of lung adenocarcinoma. Lung Cancer. 2014 Jul;85(1):40-6. doi: 10.1016/j.lungcan.2014.03.023. Epub 2014 Apr 1. — View Citation

Koike T, Terashima M, Takizawa T, Watanabe T, Kurita Y, Yokoyama A. Clinical analysis of small-sized peripheral lung cancer. J Thorac Cardiovasc Surg. 1998 May;115(5):1015-20. doi: 10.1016/S0022-5223(98)70399-X. — View Citation

Lim HJ, Ahn S, Lee KS, Han J, Shim YM, Woo S, Kim JH, Yie M, Lee HY, Yi CA. Persistent pure ground-glass opacity lung nodules >/= 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest. 2013 Oct;144(4):1291-1299. doi: 10.1378/chest.12-2987. — View Citation

Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, Shimosato Y. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995 Jun 15;75(12):2844-52. doi: 10.1002/1097-0142(19950615)75:123.0.co;2-#. — View Citation

Son JY, Lee HY, Lee KS, Kim JH, Han J, Jeong JY, Kwon OJ, Shim YM. Quantitative CT analysis of pulmonary ground-glass opacity nodules for the distinction of invasive adenocarcinoma from pre-invasive or minimally invasive adenocarcinoma. PLoS One. 2014 Aug 7;9(8):e104066. doi: 10.1371/journal.pone.0104066. eCollection 2014. — View Citation

Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya R. "Early" peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg. 2002 Nov;74(5):1635-9. doi: 10.1016/s0003-4975(02)03895-x. — View Citation

Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K, Tada H, Mitsudomi T, Tsuboi M, Shibata T, Fukuda H, Kato H; Japan Lung Cancer Surgical Study Group (JCOG LCSSG). A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011 Apr;6(4):751-6. doi: 10.1097/JTO.0b013e31821038ab. — View Citation

Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg. 2006 Feb;81(2):413-9. doi: 10.1016/j.athoracsur.2005.07.058. — View Citation

Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu H, Yatabe Y, Zakowski M, Witte B, Kuik DJ. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol. 2012 Dec;25(12):1574-83. doi: 10.1038/modpathol.2012.106. Epub 2012 Jul 20. — View Citation

Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, van Schil P, Yatabe Y; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016 Aug;11(8):1204-1223. doi: 10.1016/j.jtho.2016.03.025. Epub 2016 Apr 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of correlations between radiologic features and pathologic subtypes Evaluation of correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma about 14 days
Secondary Specificity, Sensitivity, and Repeatability The specificity, sensitivity, and repeatability of invasiveness diagnosis based on the Whole-Mount Section about 14 days
See also
  Status Clinical Trial Phase
Recruiting NCT04122833 - Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT04027946 - LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2
Not yet recruiting NCT05079022 - ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas Phase 1/Phase 2
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Recruiting NCT05550961 - APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Active, not recruiting NCT05292859 - Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Not yet recruiting NCT05565677 - Prognostic Value of Lung Cancer MicroAnatomy in 3D
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Recruiting NCT04105270 - RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT00073398 - Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04770688 - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Phase 1/Phase 2
Completed NCT04165759 - HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)
Completed NCT04086680 - The Detection of EGFR Mutations in Liquid Based Cytology Samples
Completed NCT01362790 - SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Phase 1/Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT03298763 - Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Phase 1/Phase 2
Recruiting NCT02804646 - Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Phase 4